About this study
Childhood cancer survivors have a higher risk for treatment side effects, such as muscle loss and weakness. The survivors’ muscle cells do not make enough energy to function normally.
We are studying a new way to measure the muscle function of survivors of childhood acute lymphoblastic leukemia (ALL) using OXPHOS MRI, which is a kind of imaging. A part of the muscle cell called the mitochondria makes energy for the cell. OXPHOS MRI is a way to measure how well a muscle’s mitochondria make energy. OXPHOS levels go down as muscles become weaker. We will measure OXPHOS levels in the calf muscle of ALL survivors and of healthy controls who are enrolled in the SJLIFE study.
People in the MMICCS study will get 2 OXPHOS MRI imaging exams along with testing in our Human Performance Lab. We will test muscle strength, measure muscle mass with an x-ray machine, test physical function, and take an ultrasound image of the muscle. We will also collect blood samples and a small piece of muscle tissue (biopsy) to check for changes in how the muscle and their mitochondria look, and to see if there are any changes in muscle cell DNA. The device used to collect muscle tissue has been approved by the U.S. Food and Drug Administration (FDA) for other types of tissues, but not yet for muscle.
Eligibility overview
- Enrolled in SJLIFE study
- Acute lymphoblastic leukemia (ALL) survivor or control participant
- Age 18 and up
- Low muscle mass